亚太精准医疗市场（依生态系与国家）分析与预测（2024-2034）

亚太精准医疗市场规模预计将从 2024 年的 404.4 亿美元成长到 2034 年的 1,589.2 亿美元，预测期内（2024-2034 年）的复合年增长率为 14.67%。

亚太地区的精准医疗产业由基因研究、诊断和标靶药物开发所推动。慢性病盛行率的上升、数位健康解决方案的采用以及对个人化患者护理的日益关注是这一扩张背后的主要驱动力。由于政府措施和合作研究伙伴关係，个人化医疗的发展正在加速，从而改善患者的治疗效果。此外，生物标记、次世代定序和人工智慧诊断的广泛应用正在极大地改变肿瘤学、循环系统和罕见疾病的治疗。持续投资医疗基础设施和提高公众对个人化治疗益处的认识是促使精准医疗在许多医疗环境中迅速普及的另外两个因素。这些发展使亚太地区成为尖端医学研究和技术的活跃中心，从而带来更成功的个人化治疗计划，并朝着精准的以患者为中心的护理迈进。

精准医疗正迅速成为亚太地区医疗保健创新的主要驱动力，推动着从现有的治疗模式转向更个人化、以病人为中心的照护。基因组学、人工智慧和数位健康技术的发展使得根据每位患者的基因特征和环境情况量身定制治疗方案成为可能。个人化治疗方法在该领域越来越受欢迎，尤其是对于传统治疗常常失败的罕见疾病、癌症和慢性病等疾病。

这项变更是由政府计划和公共和私营部门的精心投资所推动的。拥有加速临床试验和简化新治疗方法市场准入的法律环境的已开发国家包括中国、日本、韩国和印度。特别是在次世代定序、生物标记发现和主导诊断等领域，製药公司、生物技术公司和学术机构之间的合作研究正在产生突破性的技术，有助于进一步提高治疗的精确度。

儘管亚太精准医疗市场取得了长足进步，但仍面临先进诊断技术高成本、各国法律规范不同以及资料安全和隐私问题等障碍。医疗设施和公众对精准医疗的理解的地区差异也可能阻碍统一实施。

总体而言，强而有力的政府支持、技术发展和战略伙伴关係正在推动亚太地区精准医疗产业的发展。人们相信，该地区可以透过提供更个人化和高效的治疗方案来进一步发展这些因素，最终透过改善临床结果和患者生活品质来彻底改变患者的照护方式。

亚太精准医疗市场趋势、驱动因素与挑战

基因研究、人工智慧诊断和数位健康技术的进步正在改变传统医疗保健，推动亚太地区精准医疗市场的快速扩张。罕见疾病、癌症和慢性病的发生率不断上升，推动了对个人化护理和客製化治疗技术的需求。市场驱动因素包括政府计划、大规模投资以及生物技术、製药和学术机构之间的研究合作。良好的法律规范和医疗保健基础设施的持续进步进一步推动了市场扩张。然而，挑战依然存在，包括先进诊断设备价格高昂、需要强大的网路安全和安全的数据集成，以及各国不同的法律要求。此外，该地区医疗保健的可用性和认知度的差异也阻碍了其更广泛的普及。儘管面临这些挑战，但在持续的技术进步和政府的大力支持下，亚太地区的精准医疗产业正在成为彻底改变以病人为中心的照护和产生更好临床结果的关键产业。

产品/创新策略：本报告深入探讨精准医疗领域的最新技术进步，使公司能够推动创新并开发符合市场需求的尖端产品。

成长/行销策略：我们提供全面的市场分析并确定关键的成长机会，为您的组织提供製定有针对性的行销策略和有效扩大市场影响力的知识。

竞争策略：彻底分析竞争格局有助于您了解竞争对手的优势和劣势，并制定有效的策略以在市场上获得竞争优势。

主要市场参与企业和竞争对手的摘要

公司简介是根据从主要专家收集的意见以及对公司覆盖范围、产品系列和市场渗透率的分析而选择的。

本报告研究了亚太地区精准医疗市场，概述了市场、生态系统和特定国家/地区的趋势以及参与市场的公司概况。

目录

执行摘要

第一章 市场概述

• 市场定义
• 精准医疗：创造以病人为中心的医疗的前沿
• 精准医疗：重新构想「一刀切」的治疗方法，实现个人治疗方法
• 倡议和计划
• 精准医疗：实行技术与应用

第二章市场：产业展望

• 精准医疗市场：生态系分析
• 市场趋势
  • 先进成像与强化治疗的整合
  • 生物样本库作为精准医疗的基石
• 业界考察
  • 专利分析
  • 管道分析
  • 厚生劳动省的法律要求与框架
• 生态系摘要

第三章 区域

• 概述
• 亚太地区
  • 区域概况
  • 市场成长动力
  • 成长抑制因素
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 其他的

第四章 竞争格局

• 竞争格局
  • 协同效应活动
• 公司简介
  • Astellas Pharma Inc
  • Sysmex Corporation
  • Konica Minolta, Inc.

第五章调查方法

Introduction to Asia-Pacific Precision Medicine Market

The Asia-Pacific precision medicine market is projected to reach $158.92 billion by 2034 from $40.44 billion in 2024, at a CAGR of 14.67% during the forecast period of 2024-2034. The precision medicine industry in the APAC area is being driven by developments in genetic research, diagnostics, and targeted medicines. The increasing incidence of chronic illnesses, the incorporation of digital health solutions, and a heightened emphasis on individualised patient care are the main drivers of this expansion. The development of customised medicines is being accelerated by government initiatives and cooperative research alliances, which is improving patient results. Furthermore, with the growing use of biomarkers, next-generation sequencing, and AI-driven diagnostics, the treatment of oncology, cardiology, and uncommon diseases is changing dramatically. Ongoing investments in healthcare infrastructure and increased public knowledge of the advantages of personalised therapy are two more factors contributing to the quick adoption of precision medicine in many healthcare settings. These developments are establishing the Asia-Pacific area as a vibrant centre for cutting-edge medical research and technology, resulting in more individualised, successful treatment plans and a move towards precise, patient-centered care.

Market Introduction

Precision medicine is quickly emerging as a key driver of healthcare innovation in Asia-Pacific (APAC), ushering in a change away from established treatment paradigms and towards more individualised, patient-centric care. Customising treatments according to each patient's unique genetic profile and environmental circumstances is now possible thanks to developments in genomics, artificial intelligence, and digital health technology. Personalised treatments are becoming more and more popular in this area, particularly for rare conditions, cancer, and chronic illnesses where conventional methods frequently fail.

This change is being driven by government programs and calculated investments from the public and private sectors. Leading nations with enabling legislative environments that speed up clinical trials and make it easier for new treatments to enter the market include China, Japan, South Korea, and India. Particularly in fields like next-generation sequencing, biomarker discovery, and AI-driven diagnostics, collaborative research between pharmaceutical corporations, biotech businesses, and academic institutions is generating ground-breaking technologies that are aiding in the further improvement of treatment precision.

Although the APAC precision medicine market has made great strides, it still confronts obstacles such as the high cost of sophisticated diagnostic technology, different regulatory frameworks in different nations, and problems with data security and privacy. Uniform adoption may also be hampered by regional variations in healthcare facilities and public understanding of precision medicines.

All things considered, the combination of strong government backing, technical developments, and strategic alliances is driving the precision medicine industry in Asia-Pacific. The region is positioned to revolutionise patient care delivery as these factors develop further by providing more individualised and efficient treatment alternatives, which will eventually improve clinical outcomes and patients' quality of life.

.

Market Segmentation:

Segmentation 1: by Ecosystem

• Applied Sciences
• Precision Diagnostics
• Digital Health and Information Technology
• Precision Therapeutics

Segmentation 2: by Country

• Japan
• India
• China
• Australia
• South Korea
• Rest-of-Asia-Pacific

Market Trends, Drivers and Challenges of APAC Precision medicine Market

Advances in genetic research, AI-powered diagnostics, and digital health technologies that are transforming conventional healthcare are propelling the APAC precision medicine market's rapid expansion. The need for individualised care and customised therapeutic techniques has increased due to the rising incidence of uncommon, cancerous, and chronic illnesses. Significant market drivers include government programs, large investments, and cooperative research between biotech, pharmaceutical, and academic organisations. Market expansion is further bolstered by favourable regulatory frameworks and continuous advancements in healthcare infrastructure. But there are still issues like the expensive price of sophisticated diagnostic instruments, the necessity for strong cybersecurity and safe data integration, and the various legal requirements in different nations. Further impeding wider adoption are disparities in healthcare availability and awareness within the region. Notwithstanding these challenges, the APAC precision medicine industry is emerging as a key player in revolutionising patient-centered care and producing better clinical results thanks to sustained technical advancement and robust government backing.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in precision medicine, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• Astellas Pharma Inc.
• Konica Minolta, Inc.
• Sysmex Corporation

Table of Contents

Executive Summary

1 Market Overview

• 1.1 Market Definition
• 1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine
• 1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
• 1.4 Initiatives and Programs
• 1.5 Precision Medicine: Enabling Technologies and Applications
  • 1.5.1 Innovators
    • 1.5.1.1 3D DNA Printing
      • 1.5.1.1.1 Introduction
      • 1.5.1.1.2 Role of 3D DNA Printing
    • 1.5.1.2 RNA-Seq
      • 1.5.1.2.1 Introduction
      • 1.5.1.2.2 Role of RNA-Seq in Precision Medicine
      • 1.5.1.2.3 Key Players
    • 1.5.1.3 4D Molecular Imaging
      • 1.5.1.3.1 Introduction
      • 1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine
      • 1.5.1.3.3 Key Players
  • 1.5.2 Early Adopters
    • 1.5.2.1 CRISPR
      • 1.5.2.1.1 Introduction
      • 1.5.2.1.2 Role of CRISPR in Precision Medicine
      • 1.5.2.1.3 Key Players
    • 1.5.2.2 Blockchain
      • 1.5.2.2.1 Introduction
      • 1.5.2.2.2 Role of Blockchain in Precision Medicine
      • 1.5.2.2.3 Key Players
    • 1.5.2.3 Imaging Informatics
      • 1.5.2.3.1 Introduction
      • 1.5.2.3.2 Role of Imaging Informatics in Precision Medicine
      • 1.5.2.3.3 Key Players
  • 1.5.3 Early Majority
    • 1.5.3.1 Artificial Intelligence (AI)
      • 1.5.3.1.1 Introduction
      • 1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine
      • 1.5.3.1.3 Key Players
    • 1.5.3.2 Circulating Free DNA (cfDNA)
      • 1.5.3.2.1 Introduction
      • 1.5.3.2.2 Role of cfDNA in Precision Medicine
      • 1.5.3.2.3 Key Players
    • 1.5.3.3 Big Data
      • 1.5.3.3.1 Introduction
      • 1.5.3.3.2 Role of Big Data in Precision Medicine
      • 1.5.3.3.3 Key Players
    • 1.5.3.4 Next-Generation Sequencing (NGS)
      • 1.5.3.4.1 Introduction
      • 1.5.3.4.2 Role of NGS in Precision Medicine
      • 1.5.3.4.3 Key Players
    • 1.5.3.5 Health Informatics
      • 1.5.3.5.1 Introduction
      • 1.5.3.5.2 Role of Health Informatics in Precision Medicine
      • 1.5.3.5.3 Key players
    • 1.5.3.6 Bioinformatics
      • 1.5.3.6.1 Introduction
      • 1.5.3.6.2 Role of Bioinformatics in Precision Medicine
      • 1.5.3.6.3 Key Players
  • 1.5.4 Late Majority
    • 1.5.4.1 Polymerase Chain Reactions (PCR)
      • 1.5.4.1.1 Introduction
      • 1.5.4.1.2 Role of PCR in Precision Medicine
      • 1.5.4.1.3 Key players
    • 1.5.4.2 Microarray
      • 1.5.4.2.1 Role of Microarray in Precision Medicine
      • 1.5.4.2.2 Key Players

2 Market: Industry Outlook

• 2.1 Precision Medicine Market: Ecosystem Analysis
• 2.2 Market Trends
  • 2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment
  • 2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine
• 2.3 Industry Insights
  • 2.3.1 Patent Analysis
  • 2.3.2 Pipeline Analysis
  • 2.3.3 Legal Requirements and Framework by the MHLW
• 2.4 Ecosystem Summary

3 Region

• 3.1 Overview
• 3.2 Asia-Pacific
  • 3.2.1 Regional Overview
  • 3.2.2 Driving Factors for Market Growth
  • 3.2.3 Factors Challenging the Market
    • 3.2.3.1 Asia-Pacific Precision Medicine Market (by Ecosystem)
  • 3.2.4 Japan
    • 3.2.4.1 Japan Precision Medicine Market (by Ecosystem
  • 3.2.5 China
    • 3.2.5.1 China Precision Medicine Market (by Ecosystem),
  • 3.2.6 India
    • 3.2.6.1 India Precision Medicine Market (by Ecosystem),
  • 3.2.7 Australia
    • 3.2.7.1 Australia Precision Medicine Market (by Ecosystem),
  • 3.2.8 South Korea
    • 3.2.8.1 South Korea. Precision Medicine Market (by Ecosystem)
  • 3.2.9 Rest-of-APAC
    • 3.2.9.1 Rest-of-APAC Precision Medicine Market (by Ecosystem)

4 Competitive Landscape

• 4.1 Competitive Landscape
  • 4.1.1 Synergistic Activities
• 4.2 Company Profiles
  • 4.2.1 Astellas Pharma Inc
    • 4.2.1.1 Overview
    • 4.2.1.2 Top Products
    • 4.2.1.3 Top Competitors
    • 4.2.1.4 Analyst View
  • 4.2.2 Sysmex Corporation
    • 4.2.2.1 Overview
    • 4.2.2.2 Top Products
    • 4.2.2.3 Top Competitors
    • 4.2.2.4 Analyst View
  • 4.2.3 Konica Minolta, Inc.
    • 4.2.3.1 Overview
    • 4.2.3.2 Top Products/Product Portfolio
    • 4.2.3.3 Top Competitors
    • 4.2.3.4 Analyst View

5 Research Methodology

• 5.1 Precision Medicine Market: Research Methodology
  • 5.1.1 Data Sources
    • 5.1.1.1 Primary Data Sources
    • 5.1.1.2 Secondary Data Sources
  • 5.1.2 Data Triangulation
• 5.2 Market Estimation and Forecast

List of Figures

• Figure 1: Asia-Pacific Precision Medicine Market, $Billion, 2023, 2028, and 2034
• Figure 2: Precision Medicine: Treatment Tailored to an Individual's Genetic Structure
• Figure 3: Precision Medicine - a Multi-Faceted Approach to Patient Care
• Figure 4: Decreasing Cost ($) and Increasing Output (TB) of Genome Sequencing, 2009-2025
• Figure 5: Asia-Pacific Precision Medicine Market (by Ecosystem), $Billion, 2023, 2028, and 2034
• Figure 6: Precision Medicine Approach
• Figure 7: Evolution of Precision Medicine Technology
• Figure 8: Precision Medicine: Enabling Technologies and Applications
• Figure 9: Structured Big Data Reporting Benefits
• Figure 10: Generalized Process for the Microarray
• Figure 11: Stakeholders in Precision Medicine
• Figure 12: Number of Patents Files, 2020-2024
• Figure 13: Precision Medicine by Top Patent Owner
• Figure 14: Asia-Pacific Precision Medicine Market, $ Billion, 2023-2034
• Figure 15: Japan Precision Medicine Market, $Billion, 2023-2034
• Figure 16: China Precision Medicine Market, $Billion, 2023-2034
• Figure 17: India Precision Medicine Market, $Billion, 2023-2034
• Figure 18: Australia Precision Medicine Market, $Billion, 2023-2034
• Figure 19: South Korea Precision Medicine Market, $Billion, 2023-2034
• Figure 20: Rest-of-APAC Precision Medicine Market, $Billion, 2023-2034
• Figure 21: Synergistic Activities, by Company (January 2020- January 2025)
• Figure 22: Synergistic Activities, by Type (January 2020- January 2025)
• Figure 23: Data Triangulation
• Figure 24: Top-Down and Bottom-Up Approach

List of Tables

• Table 1: Market Snapshot
• Table 2: Application
• Table 3: Pipeline Analysis (by Company)
• Table 4: Pipeline Analysis (by Product)
• Table 5: Precision Medicine Drugs Pipeline Analysis
• Table 6: Ecosystem Summary
• Table 7: Precision Medicine Market (by Region), $Million, 2023-2034
• Table 8: Asia-Pacific Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 9: Japan Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 10: China Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 11: India Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 12: Australia Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 13: South Korea. Precision Medicine Market (by Ecosystem), $Billion, 2023-2034
• Table 14: Rest-of-APAC Precision Medicine Market (by Ecosystem), $Billion, 2023-2034